9-NITROCAMPTOTHECIN LIPOSOME AEROSOL: LACK OF SUBACUTE TOXICITY IN DOGS
暂无分享,去创建一个
[1] C. Verschraegen,et al. Alternative Administration of Camptothecin Analogues , 2000, Annals of the New York Academy of Sciences.
[2] E. Kleinerman,et al. 9‐Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice , 2000, Annals of the New York Academy of Sciences.
[3] E. Kleinerman,et al. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] B. Giovanella,et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. , 1999, International journal of oncology.
[5] C. Verschraegen,et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. , 1999, Anti-cancer drugs.
[6] S. Hirota,et al. Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38 , 1999, Japanese journal of cancer research : Gann.
[7] S. Arbuck,et al. Clinical applications of the camptothecins. , 1998, Biochimica et biophysica acta.
[8] C. Verschraegen,et al. A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor , 1998, Anti-cancer drugs.
[9] C. Nastruzzi,et al. Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion , 1997 .
[10] C. Verschraegen,et al. Phase I Clinical and Pharmacological Studies of 20‐(S)‐Camptothecin and 20‐(S)‐9‐Nitrocamptothecin as Anticancer Agents , 1996, Annals of the New York Academy of Sciences.
[11] B. Giovanella,et al. Protocols for the Treatment of Human Tumor Xenografts with Camptothecins , 1996, Annals of the New York Academy of Sciences.
[12] E. Eisenhauer,et al. Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.
[13] M. Wani,et al. Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. , 1995, Cancer research.
[14] D. Kufe,et al. Partial characterization of human leukemia U‐937 cell sublines resistant to 9‐nitrocamptothecin P , 1994, European journal of haematology.
[15] X. Gao,et al. Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. , 1994, Journal of pharmaceutical sciences.
[16] V. Knight,et al. CHARACTERIZATION AND ADMINISTRATION OF CYCLOSPORINE LIPOSOMES AS A SMALL‐PARTICLE AEROSOL , 1993, Transplantation.
[17] T. Burke,et al. Lipid bilayer partitioning and stability of camptothecin drugs. , 1993, Biochemistry.
[18] P. Pantazis,et al. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non‐tumorigenic and tumorigenic cells in vitro , 1993, International journal of cancer.
[19] K. Kohn,et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.
[20] M. Wani,et al. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. , 1986, Journal of medicinal chemistry.
[21] B. Giovanella,et al. Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice , 1999, Cancer Chemotherapy and Pharmacology.
[22] J. Waldrep,et al. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice , 1999, Cancer Chemotherapy and Pharmacology.
[23] J. Waldrep,et al. CYCLOSPORIN A LIPOSOME AEROSOL: LAC K OF ACUTE TOXICITY IN RATS WITH A HIGH INCIDENCE OF UNDERLYING PNEUMONITIS , 1997 .
[24] P. Pantazis,et al. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. , 1993, Oncology research.